P/B
16,3
Prime Medicine
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
$649.3M
Market Cap • 10/8/2026
2019
(7 years)
Founded
2022
(4 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
159,4
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,2
EPS
—
Market Cap
Market Cap
649,3M
EV
666,7M
EV/Revenue
163,7
EV/EBITDA
-3,5
EV/EBIT
-3,4
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-21,6%
Total Yield
-21,6%
Payout
0%
Retained Earnings
-979,6M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
3589,5%
Capex/Revenue
19,6%
Capex/D&A
10,8%
Capex/OCF
-0,5%
SBC/OCF
—
% PPE
55,2%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
3,1
Quick Ratio
3
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!